The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.
 
Olga Vornicova
Consulting or Advisory Role - Merck Serono; Novartis
Speakers' Bureau - BMS; Medison; MSD Oncology; Novartis
Research Funding - BMS Brazil; Lilly; MSD; Novartis; Roche
Travel, Accommodations, Expenses - BMS Brazil; Medison; MSD; Novartis; Pfizer
 
Jay Wunder
No Relationships to Disclose
 
Peter W. M. Chung
No Relationships to Disclose
 
Abha A. Gupta
No Relationships to Disclose
 
Rebecca Anne Gladdy
No Relationships to Disclose
 
Charles N. Catton
No Relationships to Disclose
 
Samer Salah
No Relationships to Disclose
 
Peter Charles Ferguson
No Relationships to Disclose
 
Kim Tsoi
No Relationships to Disclose
 
David Benjamin Shultz
No Relationships to Disclose
 
Savtaj Singh Brar
No Relationships to Disclose
 
Philip Wong
Research Funding - AstraZeneca Canada; Bristol-Myers Squibb
 
Carol Jane Swallow
No Relationships to Disclose
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Pfizer; Roche/Genentech
 
Esmail Mutahar Al-Ezzi
No Relationships to Disclose